Catalyst Pharmaceuticals Trades at 20-33% Discount with 7.5% FCF Yield
FIRDAPSE accounts for 62% of Q1 revenue and holds patents through 2035 but could face generic entry in 2032 cutting 70-80% sales. At 14.4x P/E and 8.04x EV/EBITDA, shares trade at a 20-33% discount with a 7.5% FCF yield and 19.5% upside to a $29 fair value.
1. Patent-Protected FIRDAPSE Franchise
FIRDAPSE drives 62% of Q1 revenues, generating approximately $21K per US patient based on 3-4K patients. Its U.S. patent protection extends to February 2035, securing a monopolistic position in Lambert-Eaton Myasthenic Syndrome treatment until then.
2. Binary Litigation Risk
If Hetero litigation fails, generics could enter by 2032, slashing FIRDAPSE sales by 70-80% within two to three years. A successful outcome preserves exclusivity to 2035, creating a binary catalyst that could swing share value between $16-20 in the bear case and $28-32 in the base case.
3. Valuation Metrics and Free Cash Flow Yield
At 14.4x trailing P/E versus 16-18x peers and 8.04x EV/EBITDA versus 12-16x, Catalyst trades at a 20-33% discount to sector averages. The company’s 7.5% free cash flow yield, zero debt, and $690M cash hoard underpin a probability-weighted fair value near $29 per share.
4. AGAMREE Growth and FYCOMPA Headwinds
AGAMREE represents 21.8% of revenues, targets ~15,000 patients and could achieve $100-150M peak sales before growth decelerates beyond 2027. FYCOMPA, accounting for 16% of sales, is facing generic competition and is expected to decline to 5-8% of revenues by 2028.